TISIDB

Summary
Symbol	CCR5
Name	chemokine (C-C motif) receptor 5 (gene/pseudogene)
Aliases	CKR-5; CC-CKR-5; CKR5; CD195; IDDM22; CMKBR5; chemokine (C-C motif) receptor 5; CCCKR5; CCR-5; C-C motif che ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell membrane Multi-pass membrane protein
Domain	PF00001 7 transmembrane receptor (rhodopsin family)
Function	Receptor for a number of inflammatory CC-chemokines including CCL3/MIP-1-alpha, CCL4/MIP-1-beta and RANTES and subsequently transduces a signal by increasing the intracellular calcium ion level. May play a role in the control of granulocytic lineage proliferation or differentiation. ; FUNCTION: (Microbial infection) Acts as a coreceptor (CD4 being the primary receptor) of human immunodeficiency virus-1/HIV-1.

> Gene Ontology [ TOP ]
Biological Process	GO:0002237 response to molecule of bacterial origin GO:0002407 dendritic cell chemotaxis GO:0006816 calcium ion transport GO:0006874 cellular calcium ion homeostasis GO:0006875 cellular metal ion homeostasis GO:0006968 cellular defense response GO:0007204 positive regulation of cytosolic calcium ion concentration GO:0014808 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum GO:0019058 viral life cycle GO:0019064 fusion of virus membrane with host plasma membrane GO:0019722 calcium-mediated signaling GO:0019932 second-messenger-mediated signaling GO:0030260 entry into host cell GO:0030595 leukocyte chemotaxis GO:0032496 response to lipopolysaccharide GO:0032844 regulation of homeostatic process GO:0032845 negative regulation of homeostatic process GO:0036314 response to sterol GO:0036336 dendritic cell migration GO:0039663 membrane fusion involved in viral entry into host cell GO:0044409 entry into host GO:0044800 multi-organism membrane fusion GO:0044803 multi-organism membrane organization GO:0046718 viral entry into host cell GO:0050900 leukocyte migration GO:0051208 sequestering of calcium ion GO:0051209 release of sequestered calcium ion into cytosol GO:0051235 maintenance of location GO:0051238 sequestering of metal ion GO:0051282 regulation of sequestering of calcium ion GO:0051283 negative regulation of sequestering of calcium ion GO:0051480 regulation of cytosolic calcium ion concentration GO:0051701 interaction with host GO:0051806 entry into cell of other organism involved in symbiotic interaction GO:0051828 entry into other organism involved in symbiotic interaction GO:0055074 calcium ion homeostasis GO:0060326 cell chemotaxis GO:0060401 cytosolic calcium ion transport GO:0060402 calcium ion transport into cytosol GO:0061025 membrane fusion GO:0070098 chemokine-mediated signaling pathway GO:0070296 sarcoplasmic reticulum calcium ion transport GO:0070509 calcium ion import GO:0070588 calcium ion transmembrane transport GO:0070723 response to cholesterol GO:0070838 divalent metal ion transport GO:0071216 cellular response to biotic stimulus GO:0071219 cellular response to molecule of bacterial origin GO:0071222 cellular response to lipopolysaccharide GO:0071396 cellular response to lipid GO:0072503 cellular divalent inorganic cation homeostasis GO:0072507 divalent inorganic cation homeostasis GO:0072511 divalent inorganic cation transport GO:0097305 response to alcohol GO:0097553 calcium ion transmembrane import into cytosol GO:1902656 calcium ion import into cytosol GO:1903514 calcium ion transport from endoplasmic reticulum to cytosol GO:2000021 regulation of ion homeostasis
Molecular Function	GO:0001618 virus receptor activity GO:0001637 G-protein coupled chemoattractant receptor activity GO:0001653 peptide receptor activity GO:0003779 actin binding GO:0004435 phosphatidylinositol phospholipase C activity GO:0004620 phospholipase activity GO:0004629 phospholipase C activity GO:0004896 cytokine receptor activity GO:0004950 chemokine receptor activity GO:0008081 phosphoric diester hydrolase activity GO:0008528 G-protein coupled peptide receptor activity GO:0015026 coreceptor activity GO:0016298 lipase activity GO:0016493 C-C chemokine receptor activity GO:0019955 cytokine binding GO:0019956 chemokine binding GO:0019957 C-C chemokine binding GO:0042578 phosphoric ester hydrolase activity GO:0071791 chemokine (C-C motif) ligand 5 binding
Cellular Component	GO:0009897 external side of plasma membrane GO:0098552 side of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04060 Cytokine-cytokine receptor interaction hsa04062 Chemokine signaling pathway hsa04144 Endocytosis
Reactome	R-HSA-173107: Binding and entry of HIV virion R-HSA-380108: Chemokine receptors bind chemokines R-HSA-373076: Class A/1 (Rhodopsin-like receptors) R-HSA-1280215: Cytokine Signaling in Immune system R-HSA-1643685: Disease R-HSA-162594: Early Phase of HIV Life Cycle R-HSA-418594: G alpha (i) signalling events R-HSA-388396: GPCR downstream signaling R-HSA-500792: GPCR ligand binding R-HSA-162906: HIV Infection R-HSA-162587: HIV Life Cycle R-HSA-168256: Immune System R-HSA-5663205: Infectious disease R-HSA-6783783: Interleukin-10 signaling R-HSA-375276: Peptide ligand-binding receptors R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR R-HSA-449147: Signaling by Interleukins

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04144 Endocytosis

Reactome

R-HSA-173107: Binding and entry of HIV virion
R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-1643685: Disease
R-HSA-162594: Early Phase of HIV Life Cycle
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-162906: HIV Infection
R-HSA-162587: HIV Life Cycle
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-6783783: Interleukin-10 signaling
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
R-HSA-449147: Signaling by Interleukins

Summary
Symbol	CCR5
Name	chemokine (C-C motif) receptor 5 (gene/pseudogene)
Aliases	CKR-5; CC-CKR-5; CKR5; CD195; IDDM22; CMKBR5; chemokine (C-C motif) receptor 5; CCCKR5; CCR-5; C-C motif che ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CCR5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CCR5 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27070705	Colorectal Carcinoma	Inhibit immunity (T cell function)	While two distinct subsets of myeloid cells induce an influx of T cells into the invasive margin via CXCL9/CXCL10, CCL5 is produced by these T cells and stimulates pro-tumoral effects via CCR5.
23152559	Melanoma	Inhibit immunity	Expression of CCR5 was preferentially detected on regulatory T cells (Tregs). Accordingly, tumor-infiltrating MO-MDSCs directly attracted high numbers of Tregs via CCR5 in vitro. Intratumoral injection of CCL4 or CCL5 increased tumor-infiltrating Tregs, and deficiency of CCR5 led to their profound decrease. Moreover, in CCR5-deficient mice, RMA-S and B16 tumor growth was delayed emphasizing the importance of CCR5 in the control of antitumor immune responses.
19688743	Melanoma	Promote immunity (T cell function)	Gadd45b, a signaling molecule highly up-regulated during Th1 type responses, is studied for its role in limiting tumor growth. Mouse B16 melanoma cells implanted into Gadd45b(-/-) mice grew faster than those in WT or Gadd45b(+/-) littermate controls. The defect of Gadd45b(-/-) mice in tumor immunosurveillance was attributed to the reduced expression of IFN-gamma, granzyme B, and CCR5 in Gadd45b(-/-) CD8(+) T cells at the tumor site.
28868628	Ovarian Carcinoma	Inhibit immunity (T cell function)	Ovarian cancer stem cells promote tumour immune privilege and invasion via CCL5 and regulatory T cells. The expression of its receptor, C-C motif chemokine receptor 5 (CCR5), was also increased on the surface of Tregs in ovarian cancer patients. This receptor-ligand expression profile indicated that ovarian CSCs recruit Tregs via CCL5-CCR5 interactions.
22282655	Colorectal Carcinoma	Promote immunity (infiltration); Inhibit immunity (T cell function)	We found that higher levels of CCL5 expression in human and murine colon tumor cells correlated with higher levels of apoptosis of CD8+ T cells and infiltration of T-regulatory cells (T(reg)). We also found tumor growth to be diminished in mice lacking CCR5, a CCL5 receptor, where a similar decrease in both T(reg) cell infiltration and CD8(+) T-cell apoptosis was noted. TGF-β signaling blockade diminished apoptosis of CD8(+) T cells, implicating TGF-β as an effector of CCL5 action. In support of this concept, CCL5 failed to enhance the production of TGF-β by CCR5-deficient T(reg) or to enhance their cytotoxic effects against CD8(+) T cells.
28416485	Triple-Negative Breast Carcinoma	Inhibit immunity	We demonstrate here that an autocrine CCL5-CCR5 axis is a major regulator of immunosuppressive myeloid cells (IMC) of both monocytic and granulocytic lineages. An analysis of human triple-negative breast cancer specimens demonstrated an inverse correlation between "immune CCR5" levels and the maturation status of tumor-infiltrating neutrophils as well as 5-year-survival rates. Targeting the host CCL5 in bone marrow via nanoparticle-delivered expression silencing, in combination with the CCR5 inhibitor Maraviroc, resulted in strong reductions of IMC and robust antitumor immunities.
19155524	Pancreatic Carcinoma	Inhibit immunity (infiltration)	When CCR5/CCL5 signaling is disrupted, either by reducing CCL5 production by tumor cells or by systemic administration of a CCR5 inhibitor (N,N-dimethyl-N-{{4-{[2-(4-methylphenyl)-6,7-dihydro-5H-benzocyclohepten-8-yl]carbonyl}amino}}benzyl]-N,N-dimethyl-N- {{{4-{{{[2-(4-methylphenyl)-6,7-dihydro-5H-benzocycloheptan-8-yl]carbonyl}amino}}benzyl}}}tetrahydro-2H-pyran-4-aminiumchloride; TAK-779), Treg migration to tumors is reduced and tumors are smaller than in control mice. Thus, this study demonstrates the importance of Tregs in immune evasion by tumors, how blockade of Treg migration might inhibit tumor growth, and, specifically in pancreatic adenocarcinoma, the role of CCR5 in the homing of tumor-associated Tregs.
29617574	Non-Small Cell Lung Carcinoma	Inhibit immunity	The frequency of C-C chemokine receptor 5 (CCR5) expression on circulating M-MDSCs was significantly higher in the patients than in the HDs.
29104081	Colon Cacinoma	Promote immunity	Additionally, TWS119 can induce the expression of CD62L or CCR5 to generate a population of CD62L+γδT or CCR5+γδT cells in a dose-dependent manner.
18645037	Hepatoma	Promote immunity (infiltration)	Tumor-infiltrating DCs expressed chemokine receptors CCR1 and CCR5, and T cells and macrophages expressed CCL3, a ligand for CCR1 and CCR5. Thus, we provide definitive evidence indicating that CCR1 and CCR5 and their ligand CCL3 play a crucial role in the regulation of intratumoral DC accumulation and the subsequent establishment of tumor immunity following induction of tumor apoptosis by suicide genes.
28904130	Skin Squamous Cell Carcinoma	Inhibit immunity	Analysis of tumor lesions in wild-type (WT) and CCR5KO mice revealed that lack of CCR5 lead to significant reduction in frequency of Tregs and increased of CD4 T cells into the tumors. In this study, we also demonstrated that Treg migration to the tumor microenvironment is mediated by CCR5, and these cells are promoting tumor growth via inhibition of antitumor cells such as cytotoxic CD8+T cells.
21715565	Fibrosarcoma	Promote immunity	CCR5 activation in CD4(+) cells resulted in CD40L upregulation, leading to full maturation of antigen-presenting cells and enhanced CD8(+) T-cell crosspriming and tumor infiltration. CCR5 reduced chemical-induced fibrosarcoma incidence and growth, but did not affect the onset or progression of spontaneous breast cancers in tolerogenic Tg(MMTV-neu) mice. Our results indicate that CCR5 boosts T-cell responses to tumors by modulating helper-dependent CD8(+) T-cell activation.
21792901	renal cell carcinoma; melanoma; colon carcinoma	Promote immunity (T cell function)	The CD8 tumor-infiltrating T lymphocytes in 6-gingerol-treated mice strongly expressed IFN-γ, a marker of activation of cytotoxic T lymphocytes (CTL) CD107a and chemokine receptors that are expressed on T(H) 1 cells, such as CXCR3 and CCR5.

Summary
Symbol	CCR5
Name	chemokine (C-C motif) receptor 5 (gene/pseudogene)
Aliases	CKR-5; CC-CKR-5; CKR5; CD195; IDDM22; CMKBR5; chemokine (C-C motif) receptor 5; CCCKR5; CCR-5; C-C motif che ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CCR5 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CCR5
Name	chemokine (C-C motif) receptor 5 (gene/pseudogene)
Aliases	CKR-5; CC-CKR-5; CKR5; CD195; IDDM22; CMKBR5; chemokine (C-C motif) receptor 5; CCCKR5; CCR-5; C-C motif che ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CCR5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.162	0.72
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.066	0.956
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.225	0.791
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.991	0.0791
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.097	0.929
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	2.121	0.104
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.68	0.195
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.111	0.361
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.191	0.888
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	1.809	0.185
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.536	0.471
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.13	0.541

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CCR5 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CCR5
Name	chemokine (C-C motif) receptor 5 (gene/pseudogene)
Aliases	CKR-5; CC-CKR-5; CKR5; CD195; IDDM22; CMKBR5; chemokine (C-C motif) receptor 5; CCCKR5; CCR-5; C-C motif che ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCR5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CCR5
Name	chemokine (C-C motif) receptor 5 (gene/pseudogene)
Aliases	CKR-5; CC-CKR-5; CKR5; CD195; IDDM22; CMKBR5; chemokine (C-C motif) receptor 5; CCCKR5; CCR-5; C-C motif che ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCR5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCR5. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CCR5
Name	chemokine (C-C motif) receptor 5 (gene/pseudogene)
Aliases	CKR-5; CC-CKR-5; CKR5; CD195; IDDM22; CMKBR5; chemokine (C-C motif) receptor 5; CCCKR5; CCR-5; C-C motif che ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCR5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CCR5
Name	chemokine (C-C motif) receptor 5 (gene/pseudogene)
Aliases	CKR-5; CC-CKR-5; CKR5; CD195; IDDM22; CMKBR5; chemokine (C-C motif) receptor 5; CCCKR5; CCR-5; C-C motif che ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CCR5 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CCR5
Name	chemokine (C-C motif) receptor 5 (gene/pseudogene)
Aliases	CKR-5; CC-CKR-5; CKR5; CD195; IDDM22; CMKBR5; chemokine (C-C motif) receptor 5; CCCKR5; CCR-5; C-C motif che ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CCR5 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CCR5
Name	chemokine (C-C motif) receptor 5 (gene/pseudogene)
Aliases	CKR-5; CC-CKR-5; CKR5; CD195; IDDM22; CMKBR5; chemokine (C-C motif) receptor 5; CCCKR5; CCR-5; C-C motif che ......
Chromosomal Location	3p21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CCR5 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting CCR5.

ID	Name	Drug Type	Targets	#Targets
DB04835	Maraviroc	Small Molecule	CCR5	1
DB05501	AMD-070	Small Molecule	CCR5, CXCR4	2
DB06652	Vicriviroc	Small Molecule	CCR5	1
DB12698	Ibalizumab	Biotech	CCR5, CD4, CXCR4	3
DB12960	INCB-9471	Small Molecule	CCR5	1

Browse CCR5